Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

NCT05658575 is registered in ClinicalTrials.gov with Olatec Therapeutics, Inc. as lead sponsor.

NCT NCT05658575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05658575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
Lead sponsor
Olatec Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 6, 2023
Completion date
January 31, 2027
Enrollment
300 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

acute gout flare, arthritis, gout, gout attack, gout flare, gouty arthritis, joint pain